drugset
drugset / Trial / NCT00128830

A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study

NCT00128830 ↗

Phase 2 Completed 211 enrolled Tibotec Pharmaceuticals, Ireland
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety and tolerability of etravirine, administered as part of an individually optimized antiretroviral therapy (ART), in human immunodeficiency virus Type 1 (HIV-1) infected participants.

Timeline

Start
2005-06
Primary completion
2008-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Etravirine Small molecule 200 mg —
Background Enfuvirtide Peptide — —

Indications

HIV infectious disease